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Background: The role of percutaneous coronary intervention (PCI) in the treatment of
multivessel coronary artery disease (CAD) is still controversial and widely discussed.
More liberal use of drug-eluting stents (DES) increased proportion of those patients
undergoing PCI procedure, raising a need for more clinical evidence. The recent reported
COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and
Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. We
aim to compare safety and efficacy outcomes in patients with multivessel CAD (a
pre-specified study subset) treated with BES and EES in COMPARE II trial.
Methods: COMPARE II trial is a large randomized, multicentre, non-inferiority trial with
total of 2707 patients enrolled at 12 sites across Europe, randomized in 1:2 ratio to the
treatment with BES and EES with similar 12 months dual antiplatelet therapy. Primary
endpoint was the composite of cardiac death (CD), non-fatal myocardial infarction (MI)
and target vessel revascularization (TVR).
Results: Total of 683 patients with multivessel CAD have been enrolled in COMPARE
II trial, 453 of which in BES and 230 in EES arm. There were no significant differences
in baseline characteristics such as age (64.3 vs. 63.7; p0.4), male gender (78.2% vs.
78.7%; p0.9), or presence of diabetes mellitus (23.0% vs. 25.7%; p0.4) in BES and
EES arms respectively. The lesion length and reference diameters were also similar. At 12
months, rate of CD (1.1% vs 1.3%; p1.0), MI (4.4% vs 5.7%; p0.5), target lesion
revascularization (4.2% vs 2.6%; p0.4), TVR (5.7% vs 3.9; p0.4), target lesion failure
(6.8% vs 7.4%; p0.9) and composite of CD, non-fatal MI and TVR (8.6% vs 9.1%;
p0.9) were similar in BES and EES arms, Definite and propable stent thrombosis rate
up to 12-months was also not different (1.1% in BES vs 1.3% in EES arm; p1.0).
Conclusions: Although this substudy was not powered to detect differences between the
two stents, the BES with biodegradable polymer, was found as safe and effective as the
EES even in this challenging patients population. This adds valuable evidence about
clinical outcomes with contemporary DES.
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Background: With the introduction of drug eluting stents (DES) in this decade, treatment
of patients with STEMI with these devices has emerged as a rational PCI alternative. In
spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR,
specific concerns have arisen with regard to their short- and long-term safety. We aim to
assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with
biodegradable polymer.
Methods: NOBORI 2 and eNOBORI are two large, prospective, single-arm, multi-
center, registries that enrolled 3067 and 7750 patients respectively, out of which 248 and
703 were STEMI patients. All adverse events were adjudicated by an independent clinical
event committee in NOBORI 2, while adjudication in eNOBORI (including stent
thrombosis) is ongoing. The primary endpoint was Target Lesion Failure (TLF) defined
as a composite of cardiac death (CD), target vessel related myocardial infarction (MI) and
target lesion revascularization (TLR).
Results: STEMI patients were 6013y old, 79% males, 11% with prior MI, 10% with
prior PCI and 0.7% with previous cardiac surgery. Multiple vessels were treated in 19.5%
of patients. The lesions were complex (60% B2/C type) ostial (10%), calcified (26%),
contained thrombus (49%) and 4% required bifurcation treatment. Pre- and post-dilatation
were performed in 54% and 29% of lesions respectively. At 1-month, there were no MIs
observed. Total of 5 patients died because of cardiac reasons (0.9%) and one TLR (0.17%)
and one TVR (0.4%) were found. The TLF rate was 1.0%. In the cohort of patients
followed at 3-year, 2 patients suffered a cardiac death (0.8%), 10 had an MI (4.0%) and
TLF rate was 6.1%. A total of 96% of the patients were angina free. Regarding stent
thrombosis (ST), occurring up to 3 years, total of 4 cases have been detected (1.6%), out
of which 3 cases were subacute (1.2%) and one case of late ST (0.4%). There was no very
late ST detected at 3 years follow up.
Conclusions: Use of Nobori, DES with biodegradable polymer, in the treatment of
patients with STEMI was associated with favorable short- and long-term outcomes,
confirming its safety and efficacy for the treatment of this high risk patient population.
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Background: The impact on healing and clinical outcomes of the individual DES
components is still under debate. The aim of this study is to assess vascular effects
exclusive to the type of antiproliferative drug, eluted via identical biodegradable polymer
and platform stents implanted in the porcine model of coronary injury.
Methods: A total of 37 stents were implanted with 110% overstretch in coronary arteries
of 14 domestic pigs: 13 biodegradable polymer coated paclitaxel eluting stents (BP-PES:
LUC-Chopin2, Balton), 16 biodegradable polymer coated everolimus eluting stents
(BP-EES, Carlo, Balton) and 8 control bare metal stents (BMS: Chopin2). Following 30
and 90 day observation (7 animals each) control coronary angiography was performed,
animals sacrificed and stented segments harvested for histopathological evaluation.
Results: At 30 days, BP-PES most effectively limited angiographic late loss (PES:
0.150.1 vs. EES: 0.400.3 vs. BMS: 0.50.2 mm, p0.04). This findings were
confirmed with the lowest neointimal formation in BP-PES in histology expressed as
neointimal thickness (NT) (EES: 0.38 [0.3-0.4] vs. PES: 0.12 [0.1-0.2] vs. BMS: 0.35
[0.3-0.4] mm, p0.01) at a cost of significantly delayed endothelialisation (EES:100% vs.
PES:404% vs. BMS:97.55%;p0.01)and higher inflammation (EES:1 vs. PES:
2.10.3 vs. BMS:1; p0.01. At 3 months late loss was numerically lowest in everolimus
stents (EES: 0.380.3 vs. PES: 0.520.4 vs. BMS:0.510.3 mm: p0.69). When
compared to one month, neointimal proliferation stabilized in EES, with lowest NT
among groups, whereas it increased fourfold in BP-PES and 30% in BMS (EES:
0.35[0.3-0.5] vs. PES: 0.53[0.5-0.8] vs. BMS: 0.46[0.4-0.5] mm: p0.07). Endothelial-
ization was complete and inflammation low in all studied stents.
Conclusions: Different patterns of vascular response were observed emphasizing different
properties of locally delivered drug, with typical neointimal catch up phenomenon after
paclitaxel and favorable long term biocompatibility, healing and efficacy after everolimus.
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Background: Small coronary vessels (reference diameter 2.75mm) are often associ-
ated with diabetic and female patients and remain an important challenge in interventional
cardiology. We performed a pre-specified substudy on outcome in patients with small
vessel treatment within the all-comer COMPARE II trial.
Methods: COMPARE II is a multicenter prospective randomized (2:1) trial, of Nobori,
Biolimus eluting stent with biodegradable polymer (BES) and Xience/Promus, everoli-
mus eluting stent (EES) in 2707 patients (1795 BES arm: 912 EES arm) with limited in-
and exclusion criteria. Within COMPARE II study, a total of 766 patients with at least 1
small vessel (2.75 mm) were treated, of which 513 were randomized to the Nobori BES
and 253 to the Xience/Promus EES. The primary endpoint was the composite of safety
(cardiac death, non fatal myocardial infarction) and efficacy (target vessel revasculariza-
tion) at 12 months. Data were entered electronically and continuously monitored. All
adverse events were adjudicated by an independent clinical event committee.
Results: In the small vessel subpopulation baseline patient and lesion characteristics
showed no differences, except for the average lesion length 16.359.45 versus
17.449.91, respectively BES versus EES, p0,02. The mean reference vessel diameter
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Bioresorbable Vascular Scaffolds and Bioabsorbable Polymers B167
P
O
ST
E
R
S
